AstraZeneca chronic nephrotic anemia drug Roxadustat (Rosastat) has achieved positive results in two Phase III clinical trials

recently, AstraZeneca announced that its chronic kidney disease anemiadrug(http://Roxadustat in China conducted two Phase III clinical results,trial(http://results have proved that the drug has better efficacy and safetyAbout Rosastas
Rosas is the first low-oxygen-inducing factor prosynosis hydroxylase (HIF-PH) inhibitor that not only increases the expression of erythropoietin, but also increases the expression of erythropoietin receptors and proteins that promote iron absorption and circulationIn December 2018, Rosasta was the first global regulator to obtain approval for anemia associated with patients with dependent chronic kidney disease, which is expected to be available in China in the second half of this yearThe drug is expected to generate sales of $1.97 billion in 2023MrRosa is also under regulatory scrutiny in Japan and plans to file an application in the U.Sin the third quarterThe two trials, codenamed 806 and 808, assessed the efficacy of Rosasta in treating patients with chronic kidney disease-induced anemia in China who were dialysis-dependent (DD) chronic kidney disease or non-dialysis-dependent (NDD) chronic kidney diseaseThe results showed that rosastas met the primary goal of improving hemoglobin (Hb) effectiveness, and that the improvement time of patients treated with rosastas was 23 to 27 weeks longer than the average baseline value compared to epoetin alfa therapy 　　In the analysis (http:// of the patients with elevated inflammation of C-reactive protein (CRP), rosastas also achieved stable treatment results to control the patient's hemoglobin levels, regardless of the patient's inflammatory state, compared to Epoetin alfa security
　　Roxadustat's safety in both studies was consistent with previous clinical trials 　　FibroGen is currently working with AstraZeneca to develop and commercialize rosastas in the United States, China and other markets for the treatment of chronic kidney anemia FibroGen is also working with Astellas to treat anemia in patients with chronic kidney disease and bone marrow hyperplasia syndrome in regions including Europe, the Middle East and South Africa